Safety In Silos
John Cutler

Trying to figure out what might the equivalency to feature velocity in building clinical trials.

I adopt the perspective that the product is not just the drug, but the entire trial experience. The drug is just a feature, albeit a highly regulated one, within the trial product.

I wonder if feature velocity then would be around number of sites and how fast they’re initiated, or how many endpoints are being pursued?

The X number of sites teams think they have to pursue tend to slow down study initiation and thus delay validation with caregivers and patients.

Multiple endpoints can make the protocol overly complex, delay getting started, or cause patients to drop out (dropping retention) due to the burden of the trial.

Would these in any way relate to a traditional understanding of feature velocity?